Literature DB >> 1999503

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

K Selmaj1, C S Raine, B Cannella, C F Brosnan.   

Abstract

Multiple sclerosis (MS) brain tissue, spleen, and PBMC were studied using immunocytochemistry and FACS for immunoreactivity for lymphotoxin (LT) and TNF. Both cytokines were identified in acute and chronic active MS lesions but were absent from chronic silent lesions. LT was associated with CD3+ lymphocytes and Leu-M5+ microglia cells at the lesion edge and to a lesser extent, in adjacent white matter. TNF was associated with astrocytes in all areas of the lesion, and with foamy macrophages in the center of the active lesion. In acute lesions, immunoreactivity for TNF in endothelial cells was noted at the lesion edge. No LT or TNF reactivity was detected in Alzheimer's or Parkinson's disease brain tissues but was present at lower levels in central nervous system (CNS) tissue from other inflammatory conditions, except for adrenoleucodystrophy which displayed high levels of LT in microglia. No increase in LT and TNF reactivity was detected in spleen and PBMC of MS patients suggesting specific reactivity within the CNS. These results indicate that LT and TNF may be involved in the immunopathogenesis of MS, and can be detected in both inflammatory cells and cells endogenous to the CNS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1999503      PMCID: PMC329886          DOI: 10.1172/JCI115102

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

Review 1.  The role of lymphotoxin in inflammation.

Authors:  N H Ruddle; R Homer
Journal:  Prog Allergy       Date:  1988

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes.

Authors:  D S Robbins; Y Shirazi; B E Drysdale; A Lieberman; H S Shin; M L Shin
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

4.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

5.  Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells.

Authors:  K Frei; C Siepl; P Groscurth; S Bodmer; C Schwerdel; A Fontana
Journal:  Eur J Immunol       Date:  1987-09       Impact factor: 5.532

6.  Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor.

Authors:  A Sica; J M Wang; F Colotta; E Dejana; A Mantovani; J J Oppenheim; C G Larsen; C O Zachariae; K Matsushima
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

7.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.

Authors:  I R Garrett; B G Durie; G E Nedwin; A Gillespie; T Bringman; M Sabatini; D R Bertolini; G R Mundy
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

8.  Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line.

Authors:  L B Lachman; D C Brown; C A Dinarello
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

9.  Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and interleukin 1.

Authors:  C Pukel; H Baquerizo; A Rabinovitch
Journal:  Diabetes       Date:  1988-01       Impact factor: 9.461

10.  Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni.

Authors:  I Esparza; D Männel; A Ruppel; W Falk; P H Krammer
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  119 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 3.  Cytokine/neurotrophin interaction in the aged central nervous system.

Authors:  N J Macdonald; F Decorti; T C Pappas; G Taglialatela
Journal:  J Anat       Date:  2000-11       Impact factor: 2.610

4.  Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology.

Authors:  B Bonetti; C Stegagno; B Cannella; N Rizzuto; G Moretto; C S Raine
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination.

Authors:  S Hisahara; T Araki; F Sugiyama; K i Yagami; M Suzuki; K Abe; K Yamamura; J Miyazaki; T Momoi; T Saruta; C C Bernard; H Okano; M Miura
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 6.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

7.  The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia.

Authors:  L A Pasquini; C A Calatayud; A L Bertone Uña; V Millet; J M Pasquini; E F Soto
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

8.  New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.

Authors:  Makoto Tanno; Ichiro Nakamura; Shunsuke Kobayashi; Kumiko Kurihara; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2006-11       Impact factor: 2.980

9.  Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha.

Authors:  L Probert; K Akassoglou; M Pasparakis; G Kontogeorgos; G Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Dual expression of CD45RA and CD45RO isoforms on myelin basic protein-specific CD4+ T-cell lines in multiple sclerosis.

Authors:  Y Qin; S Van Den Noort; J Kurt; S Gupta
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.